Basel, July 2, 2026 – Novartis today announced that the European Commission (EC) has approved Itvisma ® (onasemnogene ...
Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact ...
At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...
Explore opportunities with Novartis below.
Transforming the treatment and healthcare system landscape using early interventions, pioneering treatments, and innovative partnerships to avoid preventable mortality from cardiovascular disease (CVD ...
Join our network of bright and curious minds What makes building a career here so rewarding? It’s being part of a community of smart, dedicated people. Professionals you can admire, learn from, and ...
Novartis uses the open-source Drupal content management framework for many key websites, including our flagship global site Novartis.com, main country sites, portals for healthcare professionals, and ...
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Age-related diseases, including neurodegenerative diseases and cardiovascular and metabolic diseases, account for a substantial and rising portion of the global health burden. DARe scientists are ...
The mental health and wellbeing of our people is fundamental to who we are at Novartis. As an extension of our purpose to improve and extend people’s lives, we are committed to supporting our people ...
Nürnberg, 06. Juli 2026 – Tatjana Dreyer hat zum 1. Juli 2026 die Position als Head Communications & Patient Advocacy bei Novartis Deutschland übernommen. In dieser Funktion gehört sie dem Country ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results